Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.47 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.40 |
| ▸ | ABCC9 | O60706 | 1/20 | 0.40 |
| ▸ | ABCC8 | Q09428 | 1/20 | 0.40 |
| ▸ | KCNJ11 | Q14654 | 1/20 | 0.40 |
| ▸ | KCNJ8 | Q15842 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.38 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.38 |
| ▸ | PGR | P06401 | 2/20 | 0.37 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.36 |
| ▸ | SETDB1 | Q15047 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1026069 | 0.86 | CYP2A6 (0.48) | ALDH1A1POLBMAPTCYP2A6EGLN2 | |
| SCHEMBL20526615 | 0.85 | HRH4 (0.46) | ALDH1A1POLBMAPTCYP2A6EGLN2 | |
| SCHEMBL2154388 | 0.83 | EGLN2 (0.52) | ALDH1A1POLBMAPTCYP2A6EGLN2 | |
| SCHEMBL12550188 | 0.83 | MPO (0.41) | ALDH1A1POLBMAPTCYP2A6SLC6A2 | |
| SCHEMBL11617787 | 0.82 | PRKCI (0.46) | ALDH1A1POLBMAPTCYP2A6EGLN2 | |
| SCHEMBL13824727 | 0.81 | CYP2A6 (0.52) | ALDH1A1CYP2A6EGLN2SLC6A4SLC6A3 | |
| SCHEMBL11620126 | 0.81 | SLC6A4 (0.58) | ALDH1A1POLBMAPTSLC6A2SLC6A4 | |
| SCHEMBL11624802 | 0.80 | SLC6A2 (0.42) | ALDH1A1POLBMAPTCYP2A6SLC6A2 | |
| SCHEMBL3557844 | 0.80 | ALDH1A1 (0.39) | ALDH1A1POLBMAPTSLC6A2SLC6A4 | |
| SCHEMBL18324675 | 0.80 | ALDH1A1 (0.39) | ALDH1A1POLBMAPTCYP2A6EGLN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 216 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025228900-A1 | ARYLAMIDE SUBSTITUTED INDAZOLES AND THE USE THEREOF AS MEDICAMENT | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2025-11-06 | — | — | WO | disclosed |
| WO-2025049326-A1 | TRICYCLIC HETEROAROMATIC INHIBITORS OF KLK5 | BIOCRYST PHARMACEUTICALS, INC. (US) | 2025-03-06 | — | — | WO | disclosed |
| CN-114105745-B | Octabolmod intermediate and preparation method thereof | 广东东阳光药业股份有限公司 | 2024-07-23 | — | — | CN | disclosed |
| CN-112745205-B | Preparation method of simod intermediate | 广东东阳光药业股份有限公司 | 2024-04-05 | — | — | CN | disclosed |
| CN-113527250-B | Octabolmod intermediate and preparation method thereof | 广东东阳光药业股份有限公司 | 2024-01-05 | — | — | CN | disclosed |
| US-20230165867-A1 | IMIDAZOLIDINONE DERIVATIVES AND MEDICAL USE THEREOF | KANGBAIDA (SICHUAN) BIOTECHNOLOGY CO., LTD. (CN) | 2023-06-01 | — | — | US | disclosed |
| US-20230165867-A1 | IMIDAZOLIDINONE DERIVATIVES AND MEDICAL USE THEREOF | KANGBAIDA (SICHUAN) BIOTECHNOLOGY CO., LTD. (CN) | 2023-06-01 | — | — | US | disclosed |
| EP-4137491-A1 | IMIDAZOLINONE DERIVATIVE AND USE THEREOF IN MEDICINE | Chengdu Baiyu Pharmaceutical Co., Ltd. (CN) | 2023-02-22 | — | — | EP | disclosed |
| CN-114105745-A | Siponimod intermediate and preparation method thereof | 广东东阳光药业有限公司 | 2022-03-01 | — | — | CN | disclosed |
| CN-113527250-A | Siponimod intermediate and preparation method thereof | 广东东阳光药业有限公司 | 2021-10-22 | — | — | CN | disclosed |
| WO-1996026932-A1 | 2-ARYLBENZAZOLE COMPOUNDS | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 1996-09-06 | — | — | WO | disclosed |
| EP-0729457-A1 | DIAMINOCYCLOBUTENE-3,4-DIONES AS SMOOTH MUSCLE RELAXANTS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1996-09-04 | — | — | EP | disclosed |
| US-5532245-A | TO REDUCE SMOOTH MUSCLE CONTRACTIONS; TREATMENT FOR URINARY INCONTINENCE, IRITABLE BOWEL SYNDROME | AMERICAN HOME PRODUCTS CORPORATION (US) | 1996-07-02 | — | — | US | disclosed |
| US-5530025-A | SMOOTH MUSCLE RELAXANTS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1996-06-25 | — | — | US | disclosed |
| WO-1996015103-A1 | DIAMINOCYCLOBUTENE-3,4-DIONES | AMERICAN HOME PRODUCTS CORPORATION (US) | 1996-05-23 | — | — | WO | disclosed |
| WO-1996014300-A1 | N-ARYL AND N-HETEROARYL-1,2-DIAMINOCYCLOBUTENE-3,4-DIONES WITH SMOOTH MUSCLE RELAXING ACTIVITIES | AMERICAN HOME PRODUCTS CORPORATION (US) | 1996-05-17 | — | — | WO | disclosed |
| US-5506252-A | MUSCLE RELAXANTS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1996-04-09 | — | — | US | disclosed |
| US-5466712-A | Smooth muscle relaxants | AMERICAN HOME PRODUCTS CORPORATION (US) | 1995-11-14 | — | — | US | disclosed |
| WO-1995015954-A1 | HETEROCYCLIC BIPHENYLYLAMIDES USEFUL AS 5HT1D ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1995-06-15 | — | — | WO | disclosed |
| WO-1995014005-A1 | DIAMINOCYCLOBUTENE-3,4-DIONES AS SMOOTH MUSCLE RELAXANTS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1995-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230165867-A1 | IMIDAZOLIDINONE DERIVATIVES AND MEDICAL USE THEREOF | SYMPK, PAICS, CYP2C9 | ALDH1A1 702/4885POLB 1974/4885MAPT 2312/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.